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Abstract Cerebral and systemic organ microvascular
pathologies coexist with human Alzheimer’s disease (AD)
neuropathology. In this study, we hypothesised that both
cerebral and systemic microvascular pathologies exist in 4-
to 5-month-old male APPswe/PS1dE9 (APP/PS1) trans-
genic mice prior to the onset of cognitive impairment. To
assess this we examined recognition memory in both wild-
type and APP/PS1 mice using the object recognition task
(ORT; n = 11 per group) and counted thioflavin-S-positive
plaques in brain (n = 6 per group). Vascular casts of brain,
liver, spleen and kidneys were examined using scanning
electron microscopy (n = 6 per group), and the urinary
albumin-to-creatinine ratio (uACR; n = 5 per group) was
measured as an index of glomerular permeability. Murine
recognition memory was intact, as demonstrated by a sig-
nificant preference for the novel object in the ORT para-
digm. Brain sections of wild-type mice were devoid of
thioflavin-S positivity, whereas age-matched APP/PS1 mice
had an average of 0.88 ± 0.22 thioflavin-S-positive plaques
in the cortex, 0.42 ± 0.17 plaques in the dentate gyrus and
0.30 ± 0.07 plaques in the cornus ammonis 1 region. The
profiles of casted cerebral capillaries of wild-type mice were
smooth and regular in contrast to those of APP/PS1 mice
which demonstrate characteristic (0.5–4.6 lm) ‘tags’. APP/
PS1 mice also had a significantly reduced hepatic vessel
number (p = 0.0002) and an increase in the number of
splenic microvascular pillars (p = 0.0231), in the absence
of changes in either splenic microvascular density
(p = 0.3746) or glomerular ultrastructure. The highly sig-
nificant reduction in uACR in APP/PS1 mice compared to
wild-type (p = 0.0079) is consistent with glomerular
microvascular dysfunction. These findings highlight early
microvascular pathologies in 4- to 5-month-old APP/PS1
transgenic mice and may indicate an amenable target for
pharmacological intervention in AD.
Keywords Alzheimer’s disease  APP/PS1 mice 
Microvascular corrosion casting  Scanning electron
microscopy
Introduction
Dementia is characterised by heterogeneous pathologies
associated with neurodegenerative lesions that progres-
sively affect multiple cognitive domains and irreversibly
impair the ability to conduct the tasks required for inde-
pendent living [1]. Recent global estimates indicate that 46
million individuals have dementia and with 10 million new
cases of dementia occurring each year, it is expected that
by the year 2018 the global cost of dementia will exceed 1
trillion dollars [2]. AD is the most common form of
dementia, which accounts for 60–80% of all dementia
cases in the general population [2]. As the insidious
pathological pathways to neurodegeneration remain elusive
and the clinically used neurotransmitter-based therapies are
ineffective in altering disease course, it is expected that by
the year 2050 there will be 106.8 million individuals with
AD worldwide [3–6], highlighting the urgent need to
identify causative pathology.
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The proteinaceous accumulations characteristic of AD
includes parenchymal amyloid plaques and intraneuronal
tau which were first formally described by Dr. Aloysius
‘Alois’ Alzheimer in 1906 following a post-mortem
examination of 51-year-old Auguste Deter, who presented
with ante-mortem ‘delirium’ [7]. Dr. Alzheimer observed
concomitant cerebrovascular abnormalities that included
atherosclerotic changes to large cerebral vessels, a com-
plete absence of infiltrating vessels and an excessive pro-
liferation of the endothelium [7]. Cerebrovascular lesions
such as infarctions, lacunas and small vessel disease are
concomitant with AD neuropathology, which along with
amyloid plaques and neurofibrillary tangles (NFTs) addi-
tively lower the threshold for cognitive impairment [8–13].
Clinicopathological findings show that a similar magnitude
of cognitive dysfunction can be elicited by lower cerebral
densities of amyloid plaques and NFTs coinciding with
cerebrovascular lesions compared to a higher cerebral
burden of amyloid plaques and NFTs alone [12, 14]. An
ante-mortem aggregation of the vascular-based risk factors
for AD that include type-2 diabetes mellitus (T2DM),
hypertension, hypercholesterolemia and obesity is associ-
ated with an increased prevalence of cerebrovascular
lesions at post-mortem [15].
Pathological alterations to the integrity of the cere-
brovasculature may critically alter the function of the
neurovascular unit (NVU) and cause neuronal injury via an
impairment of cerebral perfusion, an unrestricted brain
entry of circulatory compounds, reduced cerebral amyloid
clearance and vascular and parenchymal accumulations of
cerebrotoxins [13, 16, 17]. Quantitative analysis of the
blood-to-brain transfer of a gadolinium contrast agent in
human participants using a high-resolution magnetic reso-
nance imaging (MRI) protocol showed an age-dependent
and region-specific disruption of the blood–brain barrier
(BBB) in the hippocampus, a brain region critical for
learning and memory [18]. Interestingly, the aforemen-
tioned study showed that hippocampal BBB disruption was
greater in individuals with mild cognitive impairment and
independent of hippocampal atrophy, demonstrating an
early role for BBB dysfunction in the pathogenesis of AD
[18]. A recent comprehensive data-driven analysis of over
7700 multiple-modality brain images, plasma and cere-
brospinal fluid biomarkers from 1171 human subjects from
the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
proposed that vascular dysfunction precedes amyloid pla-
que deposition in the pathological cascade of AD [19].
The findings of animal studies also support the proposal
that pathological changes to the vasculature are an early
event in the pathogenesis of AD. The Tg2576 transgenic
murine AD model harbouring the amyloid precursor pro-
tein (APP) 695 isoform with the double Swedish mutation
[20] exhibits cerebral hypoperfusion from 2 to 3 months of
age, which precedes the onset of amyloid plaques that
accumulate in the brain of Tg2576 mice from 11 to
13 months of age [21]. APP23 transgenic mice carrying the
APP751 isoform with a double Swedish mutation [22]
show multiple areas of vessel elimination in the cortex at
4–5 months of age, which is prior to the onset of amyloid
plaques at 6 months of age [23]. The aforementioned study
used the microvascular corrosion casting technique to
recreate the three-dimensional structure of cerebral vessels
using a polymerising resin solution followed by a scanning
electron microscopic examination of the vascular ultra-
structure [23, 24]. Interestingly, an additional study of
APP23 mice that examined cerebral hemodynamics using
magnetic resonance angiography prior to microvascular
corrosion casting showed that areas of flow voids on the
angiograms occupied the same brain regions as the vas-
cular structural deformations in the resin cerebral vascular
casts that were examined by scanning electron microscopy
(SEM; [25]).
In the present study, we use the microvascular corrosion
casting technique with SEM to recreate and examine the
fine structure of small calibre vessels of the APPswe/
PS1dE9 (APP/PS1) mouse model of AD. APP/PS1 mice
carry the ‘‘Swedish mutation’’ (APP695 isoform) in addi-
tion to an exon-9 deleted variant of presenilin-1 (PS1)
within independent vectors, which results in over-expres-
sion of these proteins primarily in the brain and heart
[26, 27]. APP/PS1 mice are reported to progressively
accumulate parenchymal amyloid plaques by 4–5 months
[28], develop cerebral amyloid angiopathy (CAA) from
6 months [28] and exhibit cognitive deficits in behavioural
tasks from 7 months of age [29, 30]. Accordingly, we have
examined both the cerebral and systemic vascular ultra-
structure of young 4- to 5-month-old male APP/PS1 mice
at the age when cerebral amyloid plaques begin to accu-
mulate, prior to development of both CAA and cognitive
deficits. We sought to determine whether disturbances of
microvascular structure and function are a systemic phe-
nomenon (rather than being CNS specific) in the APP/PS1
mouse by examining organs previously shown by I125-la-
belling studies to be associated with the metabolism of b-
amyloid, namely kidney, spleen and liver. Accordingly, we
assessed urinary albumin-to-creatinine ratios (uACR) as a
measure of glomerular microvascular function in young 4-
to 5-month-old APP/PS1 mice. Measuring renal dysfunc-
tion in AD is receiving attention as a potential clinical
marker, with a cross-sectional study of individuals with AD
identifying a high proportion with altered kidney function
[33]. Furthermore, a longitudinal study showed that men
[75 years of age with elevated uACR are more likely to
show cognitive decline over a 6-year period [34]. In
addition, we have shown that 9-month-old male APP/PS1
mice demonstrate significant splenic microvascular loss in
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addition to ultrastructural abnormalities in glomerular
capillaries compared to age-matched, wild-type littermates
[31]. Most significantly, 9-month-old APP/PS1 mice
exhibit numerous cerebral cortical microvascular microa-
neurysms and widespread extravasation of resin casting
solution from cerebral capillaries [31] that coexists with
cerebral amyloid plaques, CAA [28] and cognitive deficits
[32]. In the present study, we test the hypothesis that in 4-
to 5-month-old APP/PS1 mice pathological changes to the
cerebral, hepatic, splenic and renal microvasculature pre-
cede the onset of measurable cognitive impairment.
Materials and methods
Animals
Male APP/PS1 transgenic mice on a C57BL/6 genetic
background (The Jackson Laboratory, Bar Harbour, Maine,
USA) were mated with female C57BL/6 mice (Harlan,
Blackthorn, UK) within a specialised facility with food and
water available ad libitum. The temperature within the
facility was maintained at 21.5 ± 1 C and an automated
lighting system created 12-h light/12-h dark cycles. Pups
aged between 21 and 28 days old were removed from their
parental cage with genotyping performed by collection of
an ear biopsy. DNA extracted from the ear biopsy was
amplified using polymerase chain reaction (PCR) with
primers specific for the APP sequence. All genotyped
animals were housed in same sex social groups of up to
three littermates per cage. At 4–5 months of age, the mice
within the wild-type and APP/PS1 groups were listed in
chronological order of date of birth and each mouse was
assigned a number in sequential order. Random numbers
were generated using the ‘RANDBETWEEN(1, total
number of mice within group) function (Microsoft Excel,
Redmond, WA, USA), and mice with an assigned number
matching the random number were assigned into experi-
mental groups and caged individually. Experimental pro-
cedures were in accordance with Animals (Scientific
Procedures) Act, UK of 1986.
Open field task
The individual spontaneous locomotion and exploratory
behaviour of 4- to 5-month-old male wild-type and APP/
PS1 mice (n = 11 per group) within an open field arena
was recorded and quantitatively assessed. Mice were
selected for the experimental procedure in a random
manner and to avoid experimenter bias, their genotype was
concealed by a code that was assigned by an assistant. At
1 week prior to the behavioural task, the investigator
handled the animals individually within the testing room
for 3 min each day for 7 days, in a bid to acclimatise the
animals to the investigator and to the testing room. The
open field task (OFT) consisted of a circular arena of
58 cm in diameter with walls that were 31 cm high. The
arena was dimly illuminated by a 60 W lamp. Each animal
explored the open field arena for 5 min, and murine
behaviour was recorded by a computerised tracking system
and camera (Biosignals, New York, USA), positioned at a
distance of 2 m above the arena. Path length, linearity, the
number of rearing events (each instance that the mouse
elevated its front paws), the number of faecal pellets pro-
duced within the arena and the exploration of the centre of
the arena versus the periphery by each of the 4- to 5-month-
old wild-type and APP/PS1 mice were determined. The
open field arena was cleaned thoroughly using 70% ethanol
in a bid to reduce olfactory cues prior to introducing the
next mouse under test to the open field arena.
Novel object recognition task
Recognition memory, a form of working memory [35], was
evaluated in 4- to 5-month-old male wild-type and APP/
PS1 mice using the novel object recognition task (ORT).
The novel ORT paradigm examines the integrity of neural
processes required for the storage and recall of a previously
explored ‘familiar object’ motivating exploration of a
‘novel object’, without need for negative reinforcement
[36]. At 24 h following completion of the OFT, each ani-
mal was in turn individually placed into the open field
arena for 10 min for the acquisition phase of the novel
ORT task. The open field arena contained two randomised
objects (white balls or red cubes), secured to the floor at a
distance of 15 cm from either wall. The exploration of
either object, defined as the amount of time that an animal
positioned its snout B2 cm from the object, was recorded.
Immediately upon completion of the acquisition phase, the
animal was returned to its’ home cage for a retention period
of 3 h prior to being placed into the arena for the test phase
of the task. The test phase of the novel ORT paradigm
consisted of an individual exploration of the arena by each
animal for 10 min. The arena contained one object previ-
ously encountered by the animal during the acquisition
phase of the task and one ‘novel’ object (white ball or red
cube) that the animal had not previously explored. Murine
exploration of both objects was recorded in the same
manner as in the acquisition phase. The recognition index
(RI), defined as the amount of time that each mouse spent
exploring either object (tA or tB) divided by the amount of
time spent exploring both objects (tA or tB/tA ? tB) 9
100, was determined for each animal in both the acquisi-
tion phase and test phase of the task.
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Quantitative determination of thioflavin-S-positive
amyloid plaques in murine brain
The number of thioflavin-S-positive plaques within the cortex
and the dentate gyrus and cornus ammonis 1 (CA1) sub-re-
gions of the hippocampus were identified histologically and
counted in a blinded manner in 4- to 5-month-old male wild-
type and APP/PS1 mice (n = 6 per group) that were randomly
assigned to the experimental procedure. Each animal received
an intraperitoneal injection of heparin [Sigma-Aldrich Ltd,
Dorset, UK (180 IU/kg bodyweight (bw))] dissolved in sterile
saline solution (0.9% w/v NaCl) at a minimum of 15 min prior
to inhalation exposure to isoflurane (Isoflo Inhalation 100%
w/v Vapour, liquid isoflurane, Abbott Laboratories Ltd,
Berkshire, UK). The animal subsequently received an
intraperitoneal injection of 0.3 mL Pentobarbital sodium
(Dolethal 200 mg/mL solution for injection, Vetoquinol UK
Ltd, Buckingham, UK) and an adequate level of anaesthesia
was confirmed by loss of the pedal withdrawal reflexes. The
murine heart was exposed surgically, and the left ventricle was
carefully cannulated with a cut made to the right atrium. The
entire murine circulatory system was flushed with 20 mL
phosphate-buffered saline [(PBS) Oxoid Ltd, Hampshire,
UK] solution heated to 37 C followed by 20 mL filtered 4%
paraformaldehyde (PFA) solution [37] heated to 37 C. The
murine brain was excised from the cranial vault by careful
dissection and stored overnight in 4% PFA solution prior to
transfer to a solution of 30% sucrose (Sigma-Aldrich Ltd,
Dorset, UK) in PBS solution for up to 5 days. Each whole
brain specimen was mounted in an upright position onto a
25-mm stainless steel chuck (Leica Biosystems, Milton
Keynes, UK) containing Tissue-Tek OCT compound (Sakura
Finetek, AJ Alphen aan den Rijn, The Netherlands) and sub-
sequently cooled in 2-methylbutane (Sigma-Aldrich Ltd,
Dorset, UK) on dry ice. Each whole brain specimen was
trimmed using a cryostat (Leica CM1850, Leica Biosystems,
Milton Keynes, UK) to approximately bregma -0.94 mm
[38], and the first 20-lm coronal whole brain section was
collected using a cooled paint brush with careful transfer to a
cryoprotectant buffer (30% ethylene glycol, 25% glycerine in
PBS solution). Every seventh whole brain section was col-
lected thereafter until a depth of bregma -2.92 mm [38].
Eight whole brain sections from each animal were washed 3
times in dd.H2O and mounted onto a glass microscope slide,
pre-coated with 2% v/v aminopropyltriethoxysilane (Sigma-
Aldrich, Dorset, UK) in acetone (Sigma-Aldrich Ltd, Dorset,
UK). Each slide was placed within an increasing concentra-
tion of 70–80% ethanol (Sigma-Aldrich Ltd, Dorset, UK) for
1 min prior to being placed into a solution of filtered 1%
thioflavin-S in 80% ethanol for 15 min. The slides were then
transferred into a decreasing gradient of 80–70% ethanol
(Sigma-Aldrich Ltd, Dorset, UK) for 1 min and dd.H2O for
1 min [39]. Each slide was dried in a light-protected container
for at least 2 h and then cover-slipped using aqueous mounting
media (Vector mounting medium, Vector Laboratories, Cal-
ifornia, USA). Blinding of the APP/PS1 status for each slide
was performed using a pre-assigned code provided by an
assistant. Two areas within each cortex, dentate gyrus and
CA1 region from both hemispheres of each whole brain sec-
tion were selected at random, imaged using a 109 objective
magnification (Axio Scope A1, Zeiss, Germany) and stored
prior to blinded analysis. A single, randomly placed, counting
frame (1050 lm 9 1400 lm) was super-imposed on each of
the cortical and hippocampal regions examined and the total
numbers of plaques identified and counted using ImageJ
software. GraphPad prism software was then used to deter-
mine the average number of thioflavin-S-positive plaques for
each brain region per animal. Data are presented as
mean ± SEM for each brain region.
Microvascular corrosion casting
Male wild-type and APP/PS1 mice aged 4–5 months of age
(n = 6 per group) were randomly assigned to the experi-
mental procedure. Each animal received an intraperitoneal
injection of heparin [(2500 IU/L) in 0.9% w/v NaCl;
Ratiopharm, Gmbh] at a minimum of 15 min prior to the
administration of non-recovery anaesthesia [100 mg/kg bw
ketamine (Ketavet, Pfizer, Berlin, Germany); 16 mg/kg bw
xylazine (Rompun, Bayer, Leverkusen, Germany)]. Once an
adequate plane of anaesthesia was confirmed by loss of pedal
withdrawal reflexes, the animal was secured in a supine
position under a stereomicroscope [Leica MZ6; Leica
Microsystems (UK) Ltd; Milton Keynes, UK]. The murine
heart was surgically exposed and a cannula (Acufirm,
1428LL) carefully inserted into the aorta and secured by the
tying of a silk suture around the aorta. The murine right
atrium was cut immediately prior to the perfusion of 15 mL
saline solution [(0.9% w/v NaCl) heated to 37 C)], followed
by 15 mL [(2.5% glutaraldehyde in 0.1 M phosphate buffer
pH 7.4 (Agar Scientific, Essex, UK)] heated to 37 C, with
subsequent perfusion of 15 mL PU4ii casting solution
(VasQtec, University of Zurich, Switzerland), prepared as
directed by the manufacturer. The casted mice remained in a
supine position at room temperature for 12 h prior to the
careful removal of the brain, liver, spleen and kidneys from
each animal. Each resin-casted whole brain and kidney
specimen was bisected, and the left lobe was carefully
removed from each casted liver specimen.
Scanning electron microscopic evaluation
of cerebral, hepatic, splenic and renal vasculature
The casted brain, left hepatic lobe, spleen and kidney
specimens were individually placed into a macerating
solution of 5–7.5% potassium hydroxide solution (Sigma-
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Aldrich Company Ltd, Dorset, UK). The macerating
solution was renewed daily until all of the tissue that sur-
rounded the casted vasculature had been removed. Each
resin-casted specimen was carefully washed using dd.H2O
and placed into a dust-protected container, lined with fine
filter paper. Each specimen air-dried for 72 h [24] prior to
being secured onto an aluminium stub and homogeneously
coated with a thin layer of palladium and gold (E5100;
Quorum Technologies Ltd, East Sussex, UK) for SEM
examination.
Quantitative analysis of cerebral, hepatic
and splenic microvascular ultrastructure
The identity of each resin-casted murine brain was con-
cealed using a code that was assigned by an assistant. Areas
of cortical vasculature within each casted brain specimen
were selected at random by an assistant and imaged at
5009 using a SEM (Philips XL30, Eindhoven, Nether-
lands), at an acceleration voltage of 15 keV. The generated
micrographs were spatially calibrated using ImageJ soft-
ware (US National Institutes of Health, Bethesda, Mary-
land, USA). Ten cortical capillaries (that were not obscured
by other vessels) were selected, and their lengths as well as
diameters measured using ImageJ software. Five areas of
hepatic and splenic microvasculature were selected at
random by an assistant and imaged at 8009 and 14009,
respectively, using a SEM (ESEM, FEI Quanta 200 FEG,
Holland FEI Company) at an acceleration voltage of
10–15 keV. The generated micrographs had their identities
concealed with a number, provided by an assistant. The
number of hepatic sinusoidal vessels not concealed by
other vessels within a counting frame (dimensions of
330 lm 9 380 lm) recorded. The area occupied by sple-
nic microvasculature within the spatially calibrated
micrographs (counting frame with dimensions of
190 lm 9 220 lm) was determined using ImageJ soft-
ware. The number of splenic intussusceptive pillars (for
details see [31]) was counted within each of the coded
micrographs.
Determining the uACR in collected mouse urine
Male wild-type and APP/PS1 mice aged 4–5 months
(n = 5 per group) were randomised into the experimental
procedure and 200 lL urine collected directly from each
animal. The collected urine was then transferred into a
sterilised collection tube that subsequently had its identity
concealed by a code assigned by an assistant. The con-
centration of albumin within each of the coded urine
samples was determined using a Mouse Albumin ELISA
(Mouse Albumin ELISA Quantitation Set, Bethyl Labora-
tories Inc, Montgomery, USA) and the concentration of
creatinine determined using an enzymatic assay (Thermo
Scientific) on a Konelab Clinical Analyser at the Langford
Diagnostic Laboratory, University of Bristol, UK.
Statistical analyses
The mean values of independent variables were statistically
compared using GraphPad Prism 6 Software (GraphPad
Software Inc, California, USA). Normality of the distri-
bution was assessed using a Kolmogorov-Smirnov assess-
ment. Data sets with a p value\0.05 were deemed to be
significantly different from normal and were assessed
nonparametrically using the Mann–Whitney U test. Data
sets that were deemed to be normal were assessed para-
metrically using either an analysis of variance (ANOVA)
or t test. Data were considered to be statistically different
when p value \0.05. The data are presented in graphs
generated using GraphPad Prism software and values
shown ±standard error of the mean.
Results
Exploratory behaviour of 4- to 5-month-old APP/
PS1 mice is not significantly different from age-
matched wild-type mice
Murine spontaneous locomotion and exploratory behaviour
was assessed within a dimly illuminated open field arena.
Wild-type mice had a shorter path length (**p = 0.0069;
Fig. 1a) and path linearity (*p = 0.0308; Fig. 1b) when
compared to age-matched APP/PS1 mice. There was no sig-
nificant difference in the number of rearing events exhibited
by wild-type mice when compared to age-matched APP/PS1
mice (p = 0.6285; Fig. 1c). Similarly, the average number of
grooming events (p = 0.1883; Fig. 1d), faecal pellets pro-
duced (p = 0.1617; Fig. 1e) and the ratio of exploration of the
periphery of the arena compared to the centre (p[ 0.05;
Fig. 1f) were not significantly different between groups.
Working memory is intact in 4- to 5-month-old wild-
type and APP/PS1 mice
The recognition memory of 4- to 5-month-old wild-type
and APP/PS1 mice was assessed using the novel ORT
paradigm [40; Fig. 2]. There was no significant difference
in the exploration of either object by either wild-type
(p = 0.1536) of APP/PS1 mice (p = 0.5507; Fig. 2a)
within the arena during the acquisition phase of the task.
However, during the test phase of the novel ORT paradigm
both wild-type and APP/PS1 murine groups showed sig-
nificant preference for exploration of the ‘novel’ object
(p\ 0.05; Fig. 2b).
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APP/PS1 mice exhibit a low number of parenchymal
thioflavin-S-positive plaques with no evidence
of CAA at 4–5 months of age
Examination via fluorescence microscopy of 20-lm-thick
frozen sections of whole brain from 4- to 5-month-old
wild-type mice (n = 6 per group) stained with thioflavin-S
revealed there were no thioflavin-S-positive plaques in
either the cortex or hippocampus (data not shown). There
were a low number of thioflavin-S-positive plaques in the
cortex (Fig. 3a) and the hippocampus (Fig. 3b) in age-
matched 4- to 5-month-old APP/PS1 mice (n = 6 per
Fig. 1 OFT assessed the
spontaneous behaviour of 4- to
5-month-old wild-type and
APP/PS1 transgenic mice
during an individual exploration
of a circular arena (n = 11 per
group). The locomotor activity
of wild-type mice within the
arena was significantly lower
than age-matched APP/PS1
mice which exhibited increased
path length (**p = 0.0069;
a) and linearity (*p = 0.0308;
b). There were no statistical
differences in either the number
of rearing events (p = 0.6285;
c), grooming events
(p = 0.1883; d) or faecal pellets
(p = 0.1617; e) produced by
wild-type mice when compared
to APP/PS1 mice. Mice spent an
equal amount of time exploring
the periphery and the centre of
the arena (f). Statistical analysis
was conducted using the
unpaired t test (a–e) and two-
way ANOVA with Bonferroni’s
multiple comparison test (f) and
presented as mean ± standard
error of the mean (SEM)
Fig. 2 Recognition memory of 4- to 5-month-old wild-type and APP/
PS1 transgenic mice (n = 11 per group) was quantitatively deter-
mined within an open arena using the novel ORT paradigm. In the
acquisition phase of the behavioural task a the recognition indices
(RI) were not significantly different for either wild-type or APP/PS1
transgenic mice thus showing similar exploration of either object
within the open arena. After a 3-h time delay between the acquisition
and test phase when mice were reintroduced into the arena and
exposed to the familiar and novel object the RI was significantly
greater for the novel object demonstrating a significantly greater
exploration of novelty by both groups of mice (p\ 0.05; b).
Statistical analysis was conducted using two-way ANOVA with
Bonferroni’s multiple comparison test and data is presented as
mean ± SEM
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group), in the absence of CAA. The number of thioflavin-
S-positive plaques was significantly lower in the CA1 sub-
region of the hippocampus when compared to the cortex of
the 4- to 5-month-old APP/PS1 mice (*p = 0.0152;
Fig. 3c). There was no significant difference in the number
of plaques in the cortex and dentate gyrus (p = 0.1254) or
between either region of the hippocampus (p = 0.5375;
Fig. 3c).
Multiple ultrastructural impairments in the cerebral
cortical capillaries of 4- to 5-month-old APP/PS1
mice
An ultrastructural examination of resin-casted cortical
capillaries in the brain of 4- to 5-month-old wild-type mice
revealed a regularly spaced network of interconnected
capillaries with uniformly smooth lumenal surfaces
(Fig. 4a, c). The resin-casted cerebral cortical capillaries of
4- to 5-month-old APP/PS1 mice exhibited microa-
neurysms both within individual vessel segments as well as
spanning bifurcations. There were numerous and variously
shaped resin protrusions (Fig. 4b; white arrow) conspicu-
ous on discrete sections of capillary walls (Fig. 4d; white
arrowheads). There were no significant differences in
capillary width (p = 0.4397; Fig. 4e) or average cortical
capillaries length (p = 0.1259; Fig. 4f) of the 4- to
5-month-old wild-type when compared to age-matched
APP/PS1 transgenic mice.
Highly significant reduction in the number
of hepatic sinusoidal vessels on the serosal surface
of the left hepatic lobe of 4- to 5-month-old APP/PS1
mice
The microvasculature on the serosal surface of the hepatic
left lobe of 4- to 5-month-old wild-type mice contains
slender sinusoidal vessels with uniform diameters that form
a characteristic interconnecting pattern (Fig. 5a). The
resin-casted hepatic vessels on the surface of the left hep-
atic lobe of age-matched APP/PS1 mice had gaps in the
network adjacent to areas of more densely packed capil-
laries (Fig. 5b). Quantitation of hepatic vessel number on
the hepatic serosal surface revealed a highly significant
reduction in the number of microvessels in 4- to 5-month-
old APP/PS1 when compared to age-matched wild-type
mice (***p = 0.0002; Fig. 5c).
Fig. 3 Low numbers of thioflavin-S-positive amyloid plaques were
detected in both the cortex and hippocampus of 4- to 5-month-old
APP/PS1 transgenic mice but not in their wild-type littermates.
Representative fluorescent thioflavin-S stained micrographs of
20-lm-thick frozen brain sections showing single thioflavin-S stained
plaques in the cortical (a) and hippocampal (b) brain regions from 4-
to 5-month-old APP/PS1 mice; no thioflavin-S-positive plaques were
observed in any of the brain sections examined in wild-type mice
(data not shown). c The numbers of thioflavin-S plaques/field were
significantly lower in the CA1 region than in the cortex (*p = 0.0152;
n = 6 per group); all other statistical comparisons were non-
significant (p[ 0.05). Statistical analyses were conducted using
either a Mann–Whitney test or unpaired t test and presented as
mean ± SEM. Scale bar 200 lm
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Aberrant splenic vascular morphology
and increased intussusception within the splenic
sinuses of 4- to 5-month-old APP/PS1 mice
An ultrastructural examination of the serosal surface of the
spleen of 4- to 5-month-old wild-type mice (Fig. 6a)
revealed a dense network of smoothly contoured bulbous
venous sinuses containing intraluminal pillars (white
arrows) that are a characteristic feature of the non-sprout-
ing angiogenic process known as intussusceptive
microvascular growth. In contrast, the splenic venous
sinuses of age-matched APP/PS1 mice are thinner and have
ragged-edges (white arrowheads) compared to those of
wild-type mice (cf. Figure 6a, b). A quantitative evaluation
of murine splenic vascular ultrastructure revealed no sig-
nificant difference in splenic vascular density (p = 0.3746;
Fig. 6c); however, the number of intussusceptive pillars
within the splenic vasculature was significantly greater in
APP/PS1 mice (p = 0.0231; Fig. 6d).
Unremarkable glomerular vascular ultrastructure is
associated with a highly significant reduction
in uACR in 4- to 5-month-old APP/PS1 mice
Scanning electron microscopic examination of resin-cas-
ted replicas from sagittally bisected mouse kidneys
revealed that the glomerular capillary profiles of 4- to
5-month-old wild-type (Fig. 7a) and APP/PS1 mice
(Fig. 7b) were ultrastructurally indistinguishable. How-
ever, a quantitative evaluation of collected mouse urine
revealed a highly significant reduction in uACR in 4- to
5-month-old APP/PS1 mice when compared to age-mat-
ched wild-type mice (**p = 0.0079; Fig. 7c). In addition,
there was also a highly significant reduction in the urinary
albumin concentration in APP/PS1 mice when compared
to the age-matched wild-type mice (**p = 0.0079;
Fig. 7d). However, the urinary creatinine levels were not
significantly different between groups (p = 0.4902;
Fig. 7e).
Fig. 4 Representative scanning
electron micrographs of resin-
casted cortical vasculature
within the brain of 4- to
5-month-old wild-type (a,
c) and aged-matched APP/PS1
transgenic (b, d) mice (n = 6
per group). The intricate
network of the cerebral cortical
vessels of wild-type mice
appears to have smooth lumenal
profiles (a, c) in contrast to the
cerebral vessels of the age-
matched APP/PS1 mice that
exhibit multiple
microaneurysms along their
lengths (white arrow; b) or
across bifurcation points. Also,
variously shaped resin
extravasations lying orthogonal
to the capillary axes remain
attached to the vessel wall




groups (p = 0.4397; e) and
(p = 0.1259; f). Statistical
assessment was conducted
using an unpaired t test and data
are presented as mean ± SEM.
Scale bar 20 lm
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Discussion
Our previous work revealed multiple cerebral microvas-
cular ultrastructural impairments in 9-month-old APP/PS1
mice [31] that coexist with AD neuropathologies, namely
cerebral amyloid plaque burden, neuroinflammation and
cognitive impairment [32]. Post-mortem studies of human
AD brain tissues have previously reported concomitant
microvascular ultrastructural changes that include atrophic
and tortuous vessels in addition to the thickening of the
microvascular basement membrane [41–43]. The aim of
our present study was to quantitatively assess the fine
structure of the vasculature in young 4- to 5-month-old
APP/PS1 mice at an age that is prior to the onset of cog-
nitive impairment in this murine model to determine
whether pathological changes to the vasculature in the
brain and peripheral organs are present.
The spontaneous locomotion and exploratory behaviour
of 4- to 5-month-old wild-type and APP/PS1 transgenic
mice was assessed using the OFT paradigm (Fig. 1). The 4-
to 5-month-old APP/PS1 mice were more active within the
open field than age-matched wild-type mice (Fig. 1a, b).
This is consistent with a previous OFT study with cohorts
of APP/PS1 mice that were 8- or 15-month-old that
reported both age groups travelled a greater distance within
the open field area than age-matched wild-type mice [44].
The increased activity exhibited by APP/PS1 mice within
the arena may not be a result of increased anxiety which is
associated with increased defecation and thigmotaxis dur-
ing the OFT [44, 45]. Our findings show that APP/PS1
mice exhibited no significant preference in the exploration
of the arena and there were no significant differences in the
number of faecal pellets produced by APP/PS1 mice during
the task when compared to age-matched wild-type mice.
The APP/PS1 transgenic mice have been reported to
have an intact recognition memory at 6 months of age [46]
with deficits in spatial memory detectable from 7 months
of age [30, 32, 44]. Accordingly, we examined the working
memory of 4- to 5-month-old mice within the novel ORT
paradigm (Fig. 2) and found that both groups of mice
showed a significant preference for the exploration of an
object not previously encountered during the acquisition
phase of the trial (Fig. 2b). This finding suggests that the
recognition memory of 4- to 5-month-old wild-type and
APP/PS1 mice are intact and that 4- to 5-month-old APP/
PS1 mice represent a time point in the pathogenesis of AD
in this murine model that is prior to the onset of cognitive
impairment.
The cerebral amyloid plaque burden in 4- to 5-month-
old mice was fluorescently determined using the
Fig. 5 Representative scanning
electron micrographs of resin-
casted hepatic vasculature of the
left hepatic lobe within 4- to
5-month-old wild-type (a) or
APP/PS1 (b) mice (n = 6 per
group). The hepatic
angioarchitecture on the serosal
surface of the left lobe consists
of a network of interconnected
vessels that have uniform
diameters (a). The hepatic
vasculature on the left lobe
serosal surface of age-matched
APP/PS1 mice contained areas
of vessel elimination that were
surrounded by densely crowded
vessels (b). A quantitative
evaluation of murine hepatic
vessel number revealed a highly
significant reduction in the
number of hepatic sinusoidal
vessels in APP/PS1 transgenic
mice when compared to age-
matched wild-type littermates
(***p = 0.0002; c). Statistical
analysis was conducted using an
unpaired t test and data are
presented as mean ± SEM.
Scale bar 100 lm
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methylated primuline, thioflavin-S [47] histological stain,
which competes for the same binding site on amyloid
plaques as the widely used Congo red stain [48]. We found
no parenchymal or vascular thioflavin-S-positive plaques in
either the cortex or hippocampus of 4- to 5-month-old
wild-type mice, whereas the age-matched APP/PS1 mice
had a very low number of plaques in the cortex and hip-
pocampus in the absence of CAA (Fig. 3), which is con-
sistent with previous reports [28, 49]. The APP/PS1
transgenic murine model of AD does progressively accu-
mulate cerebral amyloid plaque deposits in the cortex and
hippocampus brain region between the ages of
4–12 months of age [28]. A similar cortical and hip-
pocampal specific deposition of amyloid plaques has been
described in human brain tissues [50].
We replicated the cerebrovasculature of 4- to 5-month-
old mice using the microvascular corrosion casting tech-
nique with a polyurethane-based PU4ii casting resin
(Fig. 4) that had favourable physical characteristics such as
a low viscosity, elasticity and minimal shrinkage [51]. The
resin-casted murine cerebral capillaries we recreated and
observed by SEM had an average diameter of 4.1 lm in
wild-type mice and 4.3 lm in APP/PS1 mice (Fig. 4e),
which is similar to the baseline capillary diameters of
4.4 lm previously reported in anaesthetised C57BL/6J
mice [52]. This supports an accurate replication of the
murine cerebral capillary network using the microvascular
corrosion casting technique.
We consistently observed multiple clustered resin
extravasations (of \5 lm in length) attached to cerebral
capillary lumens within brains of 4- to 5-month-old APP/
PS1 mice but not age-matched wild-type animals (Fig. 4b,
d). These structures suggest a breakdown of the BBB in 4- to
5-month-old APP/PS1 mice, which is prior to the onset of
cognitive impairment in this murine AD model. The casting
resin solution may have leaked through or between adjacent
endothelial cells during its polymerisation within the vessel
wall due to an aberrant increase in the permeability of the
cerebral microvessels in 4- to 5-month-old APP/PS1 mice.
An increased cerebrovascular permeability has been
described previously in 9-month-old APP/PS1 mice using
corrosion casting with SEM [31] and 12-month-old APP/
Fig. 6 Representative scanning electron micrographs showing resin-
casted vasculature on the serosal surface of the spleen of 4- to
5-month-old wild-type (a) and age-matched APP/PS1 (b) mice
(n = 6 per group). The serosal surface of the murine spleen is covered
with densely venous sinuses that contain differently sized intussus-
ceptive pillars (white arrow; a). The venous sinuses on the splenic
serosal surface of APP/PS1 transgenic mice appear irregular (white
arrowheads; b) and also contain intussusceptive pillars (white arrows;
b). There was no significant difference in splenic microvascular
density between the murine groups (p = 0.3746; c); however, there
was a significant increase in the number of intussusceptive pillars in
the splenic microvasculature of 4- to 5-month-old APP/PS1 mice
when compared to age-matched wild-type mice (*p = 0.0231; d).
Statistical assessment was conducted using either Mann–Whitney or
unpaired t test. Data are presented mean ± SEM. Scale bar 50 lm
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PS1 mice via electron microscopy and use of an intra-
venously administered Evans-blue dye [53] as well as in
cohorts of 14-month-old or 24-month-old APP/PS1 mice
using MRI detection of a gadolinium-based contrast agent
[54]. Furthermore, an age-dependent pericyte-loss in murine
models of deficient platelet-derived growth factor receptor
beta (PDGFR-b) signalling showed cerebrovascular
degeneration, increased BBB permeability with an unregu-
lated brain entry and perivascular accumulation of serum-
derived proteins preceded and most likely contributed to the
secondary degenerative changes in neuronal structure, cir-
cuitry and behaviour in the novel ORT paradigm [55].
Our previous published findings describe the microvas-
cular ultrastructural impairments in the spleen and kidneys of
9-month-old APP/PS1 mice. We showed that 9-month-old
APP/PS1 mice have a significant reduction in splenic
microvascular density and exhibit ultrastructural impair-
ments in glomerular capillaries [31]. The findings of our
present study show microvascular ultrastructural impair-
ments in the liver, spleen and kidneys of APP/PS1 mice at
4–5 months of age. This is particularly relevant as the
intravenous administration of a 125I-Ab-40 tracer to wild-
type and APP/PS1 mice showed that the peripheral clearance
of Ab-40 peptide occurred via the liver, spleen and kidneys
[56]. Here we observed a highly significant reduction in the
number of sinusoidal vessels on the serosal surface of the left
hepatic lobe of 4- to 5-month-APP/PS1 mice when compared
to age-matched wild-type mice (Fig. 5). Interestingly, find-
ings of a previous study showed that the perfusion on the
surface of left hepatic lobe of C56BL/6 mice was reduced by
35% between the ages of 0.8–24 months of age [57]. Fur-
thermore, ageing-related changes to hepatic sinusoidal ves-
sels such as loss of fenestration and endothelial thickening
have been described in human liver specimens at post-mor-
tem [58]. Additionally, ligation of the portal vein and coeliac
artery in rats was shown to impede the cerebral clearance of
Ab 1–40 peptide [59], suggesting that the aberrant hepatic
structural changes we observed in 4- to 5-month-old APP/
PS1 mice could negatively impact upon the cerebral clear-
ance of Ab 1–40 peptide, which could promote amyloid
plaque burden and CAA.
We observed aberrant venous sinus morphology in the
splenic microvasculature of 4- to 5-month-old APP/PS1
mice when compared to age-matched wild-type mice
Fig. 7 Representative scanning electron micrographs of murine
glomerular microvasculature from 4- to 5-month-old wild-type
(a) and APP/PS1 transgenic (b) mice (n = 6 per group) showing
similar glomerular capillary profiles in both murine groups. A
quantitative determination of the uACR in collected urine from 4- to
5-month-old wild-type and APP/PS1 (c–e) mice (n = 5 per group)
revealed a significant reduction in uACR in APP/PS1 mice
(**p = 0.0079; c) associated with a reduction in albumin excretion
(**p = 0.0079; d) but not creatinine clearance (p = 0.4902; e) when
compared to age-matched wild-type mice. Statistical evaluation
conducted using either Mann–Whitney test or unpaired t test. Data
are presented as mean ± SEM. Scale bar 20 lm
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(Fig. 6). The splenic microvascular changes were coinci-
dent with an increased number of intussusceptive pillars
that are distinctive features of ‘in-itself’ microvascular
growth, first observed within casted replicas of vasculature
within rat lung [60, 61]. In contrast to classical sprouting
angiogenesis, intussusceptive angiogenesis (IA) is energy
efficient, faster and involves the formation of intraluminal
pillars that fuse together to split an existing vessel into two
vessels [62]. IA is a ubiquitous process which has been
proposed to be regulated by microhemodynamics [63] and
previously reported to occur in the vasculature of rats, mice
and humans [64]. Intussusceptive angiogenesis has also
been observed in murine models of colitis, in which pillars
are observed as ‘pits’ in corrosion casts of the mucosal
plexus at 4–7 days following chemical induction of colitis,
as an adaptive response to heightened metabolic demand
due to the onset of inflammation [63]. Interestingly, these
authors report an intussusceptive-mediated remodelling of
the entire mucosal plexus by 4 weeks, attributed to
enhanced survival of this murine model [63]. We have also
previously shown, by SEM of vascular casts, that there is
also a 30% reduction in splenic microvasculature in
9-month-old APP/PS1 transgenic mice as compared to age-
matched wild-type mice [31]. Taken together, these data
support the assertion that the significant increase in intus-
susceptive pillars in the spleen at 4–5 months of age
reflects an early splenic hemodynamic compromise, which
leads to the more substantial vessel loss observed in
9-month-old APP/PS1 mice.
We observed no striking differences in murine
glomerular capillary morphology in APP/PS1 mice com-
pared to wild-type mice (Fig. 7). However, we identified a
highly significant and consistent reduction in the uACR of
4- to 5-month-old APP/PS1 mice, compared to wild-type
mice (Fig. 7c). The findings of our present study indicate
an aberrant functioning in renal albumin excretion, prior to
the onset of cognitive deficits in young 4- to 5-month-old
APP/PS1, warranting a further examination of glomerular
capillary structure and function in young APP/PS1 mice.
Interestingly, a nuclear magnetic resonance metabolomic
study of 4-month-old APPswe/tau AD mice [65] revealed
elevated markers of oxidative stress in urine, which similar
to our study, is also prior to the onset of cognitive
impairment in this murine model [65]. Furthermore, a
study of[2100 individuals with a mean age of 56 years old
reported there to be a strong association between a reduc-
tion in the glomerular filtration rate and the prevalence of
white matter hyperintensities (WMH), observed during
MRI, which were reported to be independent of hyperten-
sion [66]. WMH include the demyelination of axons, tissue
rare fraction and gliosis and were reported in a meta-
analysis of longitudinal MRI studies to be predictive of an
increased rate of cognitive decline [67].
Taken together, the findings of our study, in young
cognitively healthy 4- to 5-month-old APP/PS1 mice with
a low number of parenchymal amyloid plaques with no
CAA, reveal early pathological changes to the cerebral
cortical capillaries, hepatic sinusoidal vessels, splenic
venous sinuses in addition to impairments in renal albumin
clearance that may be early indicators of progression to
severe disease in this experimental AD murine model.
These findings warrant further examination of the role that
cerebral and systemic microvascular pathologies play in
the progression of neurodegeneration to determine whether
the vasculature is a diagnostic target with prophylactic
efficacy in slowing neurodegeneration.
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